Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

PURPOSE OF REVIEW: Psoriatic arthritis (PsA) is an inflammatory arthritis causing significant joint damage and impaired quality of life. A treat to target approach has revolutionized the care of patients with rheumatoid arthritis over the last decade. There is now increasing interest in a similar approach in PsA, as it seems that ongoing joint inflammation predicts subsequent damage and loss of function. RECENT FINDINGS: A 2011 European League Against Rheumatism review highlighted a lack of evidence for treat to target in PsA. However, with the development of the minimal disease activity criteria, a target is available and preliminary results from the first randomized treat-to target study (Tight Control of PsA Study) using these criteria have shown significant benefit in joint and skin disease activity and patient-reported outcomes. SUMMARY: Early evidence has shown the potential benefit of a treat-to-target approach in PsA and further research is needed to optimize treatment pathways for all subtypes of the disease.

Original publication




Journal article


Curr opin rheumatol

Publication Date





107 - 110


Anti-Inflammatory Agents, Non-Steroidal, Antirheumatic Agents, Arthritis, Psoriatic, Humans, Outcome Assessment (Health Care), Severity of Illness Index